TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03710200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bologna 00+S. cerevisiae yeast
Description: Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bologna 1+S. cerevisiae yeast
Description: Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio2+S. cerevisiae yeast
Description: Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICARDA+S. cerevisiae yeast
Description: Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bologna 1+sourdough
Description: Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio 2+sourdough
Description: 109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICARDA+sourdough
Description: Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grossi+sourdough
Description: Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
Study: NCT03894813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics and Metronidazole
Description: Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Vaginal
Description: Metronidazole Suppositories,qd, 7 days
Study: NCT02476539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022
Study: NCT02941718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Advancement Counseling
Description: Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Information
Description: Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
Study: NCT04422678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
Study: NCT03056508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition
Description: On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
Study: NCT03038828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, Injection
Description: Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, Injection
Description: Immunotherapy
Study: NCT01677377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
Study: NCT03204734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Description: endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
Study: NCT00660634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Revascularization
Description: Angioplasty/Stenting of femoro-popliteal lesions
Study: NCT05252780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Body, My Rhythm, My Voice
Description: My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
Study: NCT04082819

Intervention type: DEVICE
Group type: OTHER
Intervention: Contec CMS50EW
Description: Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Contec CMS50EW
Description: Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Contec CMS50EW
Description: Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer
Description: Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer
Description: Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer
Description: Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
Study: NCT02656693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online weight management program
Description: Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online weight management program
Description: Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population health management support
Description: Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
Study: NCT01271296

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquorice
Description: 24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Description: 200 ml pink grapefruit juice three times a day, taken orally, for three days.
Study: NCT02111759

Intervention type: PROCEDURE
Group type: OTHER
Intervention: knee flexion angle 1
Description: 0 degrees of knee flexion during ACL graft fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: knee flexion angle 2
Description: 30 degrees of knee flexion during ACL graft fixation
Study: NCT04553380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic insulin
Description: 1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basic insulin
Description: 1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night.
Study: NCT03723304

Intervention type: PROCEDURE
Intervention: Bridging followed by transplant
Description: Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant

Intervention type: PROCEDURE
Intervention: Direct liver transplant
Description: Direct liver transplant (no neoadjuvant approaches during the waiting time period)
Study: NCT05446818

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanol (CF)
Description: 2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanol (CF)
Description: 2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: 2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: 2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
Study: NCT01264705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab (0.3 mg/kg) and sorafenib
Description: Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab (1.0 mg/kg ) and sorafenib
Description: Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab (3.0 mg/kg) and sorafenib
Description: Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
Study: NCT03924167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weaving Healthy Families Program
Description: The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
Study: NCT01124006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Sterile water for injection
Study: NCT03518255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature video
Description: After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
Study: NCT03679507

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Ultrasound Therapy
Description: Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low Intensity Ultrasound Therapy
Description: Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhancing CBD oil penetration into joints by sonophresis
Description: High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
Study: NCT01600144

Intervention type: OTHER
Intervention: digital mammography
Description: data collection
Study: NCT00500435

Intervention type: PROCEDURE
Intervention: Extraperitoneal Laparoscopic Lymphadenectomy
Description: Laparoscope used to find and remove para aortic lymph nodes in abdomen.
Study: NCT02840799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate (KNO3)
Description: The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride (KCl)
Description: Potassium Chloride (KCl) is the matching placebo control drug in this trial.
Study: NCT03485872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Screening and Referral Information
Description: Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Demographic and quality of life questionnaires; standard care provided by participants' GPs
Study: NCT03296319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Echocardiography guided fluid administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Echocardiography guided fluid administration
Study: NCT00959985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve
Description: Worn for a minimum of 12 hours per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve
Description: Worn for a minimum of 12 hours per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve
Description: Worn for a minimum of 12 hours per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-Stretch Compression Bandage
Description: Worn overnight at least 5 nights of the week
Study: NCT01712399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
Study: NCT04112485

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdiscectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdiscectomy
Study: NCT03622866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-high pulse width stimulation
Description: Algovita Spinal Cord Stimulation System with associated components

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pulse width stimulation
Description: Algovita Spinal Cord Stimulation System with associated components
Study: NCT02655237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix Placebo
Description: Relugolix placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix Placebo
Description: Relugolix placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Leuprorelin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Placebo
Description: Leuprorelin placebo-matching injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Placebo
Description: Leuprorelin placebo-matching injections
Study: NCT02572310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplex High Viscosity Bone Cement
Description: high viscosity bone cement for total knee replacement
Study: NCT02580630

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in running and jumping
Description: Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in running and jumping
Description: Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection with Glucocorticosteroid
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection with local anaestethic
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).